WO2000015102A1 - Correction d'attributs pour la detection et/ou la surveillance continue d'analytes - Google Patents

Correction d'attributs pour la detection et/ou la surveillance continue d'analytes Download PDF

Info

Publication number
WO2000015102A1
WO2000015102A1 PCT/US1999/020796 US9920796W WO0015102A1 WO 2000015102 A1 WO2000015102 A1 WO 2000015102A1 US 9920796 W US9920796 W US 9920796W WO 0015102 A1 WO0015102 A1 WO 0015102A1
Authority
WO
WIPO (PCT)
Prior art keywords
attribute
sensor
analyte
biological fluid
tissue
Prior art date
Application number
PCT/US1999/020796
Other languages
English (en)
Other versions
WO2000015102A9 (fr
Inventor
Michael R. Hatch
Jonathan A. Eppstein
Stuart Mcrae
Original Assignee
Spectrx, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spectrx, Inc. filed Critical Spectrx, Inc.
Priority to EP99945635A priority Critical patent/EP1112021A1/fr
Priority to CA002343762A priority patent/CA2343762A1/fr
Priority to US09/786,830 priority patent/US6918874B1/en
Priority to JP2000569690A priority patent/JP4531983B2/ja
Publication of WO2000015102A1 publication Critical patent/WO2000015102A1/fr
Publication of WO2000015102A9 publication Critical patent/WO2000015102A9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14507—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood
    • A61B5/1451—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood for interstitial fluid
    • A61B5/14514—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood for interstitial fluid using means for aiding extraction of interstitial fluid, e.g. microneedles or suction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement

Definitions

  • the present invention relates to a system and method for the compensation of assay measurements of analytes from small quantities of biological fluids harvested from tissue of a subject utilizing conditions at the harvesting and assay or measurement site.
  • Current analyte assay devices suffer from inaccuracies resulting from a variety of confounding conditions at the harvesting site. For example, blood glucose meters adjust an assay measurement for ambient temperature conditions associated with the glucose test strip when it is inserted in the meter.
  • the conditions include, but are not limited to, humidity, temperature, ambient light, pressure, etc. For example, this is particularly the case in a system that measures a glucose concentration from blood or interstitial fluid collected in a harvesting device that is placed in or about the surface of a tissue. Attribute compensation is even more important in a system that monitors an analyte on a continuous basis from a harvesting device that is kept in contact with the tissue for several hours, days or even weeks. Through the use of appropriate sensors, these conditions may be monitored and compensated for in the desired assay measurement.
  • At least one sensor is provided to measure an attribute associated with the biological fluid harvesting operation of a device or the assay of the biological fluid for one or more analytes by the device.
  • attributes, or conditions, at the harvesting site of the fluid or within the fluid handling portions within the device may affect the accuracy of the assay or other operational parameters of the device.
  • the types of sensors used are based upon the conditions that are measured.
  • An operational parameter of the harvesting device is compensated for (i.e., adjusted) based on the sensed attribute. Examples of attributes are temperature, pH, conditions of the tissue affecting fluid productivity, etc.
  • the present invention is useful in a system that performs a single (one time) measurement of an analyte in a biological fluid of a subject from a harvesting device placed in contact with the tissue, as well as in a system that continually monitors an analyte from a subject from such a harvesting device.
  • an analyte in a biological fluid of a subject may be repeatedly assayed at regular and frequent intervals by the system and method of this invention.
  • FIG. 1 is a block diagram illustrating a system according to one embodiment of the present invention.
  • FIG. 2 is a diagram of a sensor head showing the position of attribute sensors according to the invention.
  • FIG. 3 is a diagram showing the use of a vacuum/pressure sensor according to the invention.
  • FIG. 4 is a block diagram of the components of an assay meter forming part of the system of FIG. 1.
  • FIG. 5 shows the use of compensation data in graphical form to compensate an assay measurement for temperature.
  • FIG. 6 is a diagram delineating the steps that may be performed by a process according to the present invention.
  • FIG. 7 is a block diagram of a system according to another embodiment of the present invention.
  • analyte may mean one analyte or more than one analyte.
  • biological membrane means the structure separating one area of an organism from another area of the organism, such as a capillary wall, or the outer layer of an organism which separates the organism from its external environment, such as skin, buccal mucosa or other mucous membrane.
  • epidermal tissue when used herein is mean to mean skin, mucosa and linings of the body cavities of an organism.
  • tissue means an aggregate of cells of a particular kind, together with their intercellular substance, that forms a structural material. At least one surface of the tissue is preferably, but not necessarily, accessible to electromagnetic radiation so that one embodiment of the invention can be carried out.
  • the preferred tissue is the skin.
  • Other tissues suitable for use with this invention include mucosal tissue and soft organs.
  • suction or “pressure” relates to the relative pressure as compared to the internal pressure of the organism to which the system is interfaced. "Vacuum” is used synonymously with the term “suction.”
  • biological fluid means blood serum, whole blood, interstitial fluid, lymph fluid, spinal fluid, plasma cerebrospinal fluid, urine, prostatic fluid, bile, pancreatic secretions, or any combination of these fluids.
  • Other fluids that may be harvested from the surface of various tissues include fluids selected from the group consisting of mucus, saliva, breast milk, tears, gastric secretions and perspiration.
  • Interstitial fluid means the clear fluid that occupies the space between the cells in the body. It is also contemplated that biological fluids can be harvested from beneath the surface of tissue of other organs, particularly during operative procedures.
  • microporation means the artificial formation of a small hole, opening or pore to a desired depth in or through a biological membrane, such as skin or mucous membrane, or the outer layer of an organism to lessen the barrier properties of this biological membrane to the passage of biological fluids, such as analytes from within the biological membrane or the passage of permeants or drugs from without the biological membrane into the body for selected purposes, or for certain medical or surgical procedures.
  • the size of the hole or "micropore” so formed is approximately l-1000 ⁇ m in diameter. It is to be understood that the term “micropore” is used in the singular form for simplicity, but that multiple openings or pores may be formed by the integrated device according to the present invention.
  • harvesting device means a device suitable for being placed in contact with tissue for collecting a biological fluid sample from the tissue (preferably through the micropores so created) and analyzing the biological fluid to determine a characteristic thereof.
  • the harvesting device may be designed for one time, i.e., discrete use, or may be designed to be placed in contact with the tissue for longer periods of time, e.g., hours, days or weeks, for periodic, continual or continuous analyte monitoring.
  • the harvesting device may optional include a porating element (as defined below) located thereon.
  • porating element is meant to include any means of forming a micropore, hole or opening described above, including by thermal ablation, mechanically breaching the tissue by lancet or needle, and other known techniques.
  • An example of a mechanical porating element is disclosed in published PCT application WO 9800193, entitled, “Multiple Mechanical Microporation Of Skin Or Mucosa.”
  • Another porating technique suitable for use in connection with this system is disclosed in PCT Application No. PCT/US99/15967 entitled “Controlled Removal Of Biological Membrane By Pyrotechnic Charge For Transmembrane Transport,” filed July 14, 1999.
  • the term “continuously” or “continually” when used in connection with a analyte monitoring system means acting on an ongoing basis at a frequency or event rate that may vary depending on a particular application of the system.
  • the output of the sensor may be read on a periodic basis, such as every minute, several minutes, hour, several hours, etc.
  • the sensor output is optionally sampled multiple times, so as to obtain a plurality of readings relatively close in time, whereby an average or other adjustment of those multiple readings is made for determining a final reading that is displayed or logged.
  • analyte means any chemical or biological material or compound suitable for passage through a biological membrane by the technology taught in this present invention, or by technology previously known in the art, of which an individual might want to know the concentration or activity inside the body.
  • Glucose is a specific example of an analyte because it is a sugar suitable for passage through the skin, and individuals, for example those having diabetes, might want to know their blood glucose levels.
  • Other examples of analytes include, but are not limited to, such compounds as sodium, potassium, bilirubin, urea, ammonia, calcium, lead, iron, lithium, salicylates, and the like.
  • An “attribute” is a physical condition present at the harvesting site, assay site, or otherwise associated with the operation of the harvesting device.
  • An example of an attribute is temperature.
  • Other attributes or conditions that are useful to be measured are humidity, ambient light, pressure, vacuum, tissue tone, tissue thickness, tissue moisture content, oxygen, pH, etc.
  • FIG. 1 illustrates one embodiment of a system comprising a harvesting device 10 and an assay meter 70.
  • the harvesting device 10 comprises collects a sample of biological fluid from tissue such as skin, which fluid is collected through an opening 20 on the skin contact side 12.
  • the harvesting device 10 may include incorporated thereon or therein tissue penetrating or porating means, such as a lancet, thermal ablation (optically or electrically heated) such as disclosed in U.S. Patent No. 5,885,211. See also PCT applications PCT/US99/16378, filed July 20, 1999; PCT7US99/04990, filed March 5, 1999 and PCT/US99/04983, filed March 5, 1999 for variation configurations of a harvesting device that includes optional on-board tissue penetrating or porating elements.
  • the harvested fluid is moved by vacuum applied over the opening 20 and/or by capillary action, for example, such that the fluid flows through, across, or on the analyte detection strip or sensor 50.
  • the analyte sensor 50 is coupled by an optical or electrical link 60 to the assay meter 70.
  • One or more sensors 40 are positioned in the harvesting device 10 to measure conditions at the harvesting site at the time the biological fluid is harvested.
  • the sensors 40 are coupled by electrical or optical links 30 to the assay meter 70.
  • the type of sensor depends on the type of attribute or condition(s) measured.
  • the attribute may be temperature, humidity, ambient light, pressure, vacuum, tissue conditions indicative of fluid productivity (tissue tone, tissue thickness, and/or tissue moisture content) etc., or any combination thereof.
  • the point of measurement also depends on the type of attribute or condition(s) measured. Proximity to the assay is important for measuring all environmental dependencies of the assay except for those, which are common to the measurement environment such as humidity, pressure or vacuum.
  • a hose is provided to supply suction or vacuum to the harvesting device to suck fluid from the tissue into the harvesting device and onto the analyte sensor. This hose provides a mechanism to measure environmental parameters along the hose that would be consistent with the environment at the assay such as humidity, pressure and vacuum level.
  • Those environmental dependencies which should be measured near the assay include ambient light, pH and temperature. To correct for assay temperature dependence the temperature measurement point should be as close to the assay as possible within the same housing material but usually not in contact with the sample.
  • the pH of the fluid being measured can be used to compensate for pH effects on the assay and may be changed by the assay process, therefore pH should be measured in the sample just before the assay in the flow channel.
  • Tissue characteristics such as tone, thickness and moisture content should be measured close to the sample site on similar tissue. For example, if the sample site is on the mid-volar forearm tissue characteristics should be measured on the mid-volar forearm close to the site. Variations in characteristics have been measured between lower mid, and upper volar forearm sites.
  • Temperature is particularly important when the harvesting device 10 is pait of a discrete or continual glucose monitoring system.
  • an attribute sensor 40 that is responsive to temperature is preferably placed as close as possible to the analyte sensor 50 (if not on it) so that the effects of temperature variation on the analyte sensor can be minimized.
  • Many types of temperature sensors are known in the art that are suitable for use in connection with the present invention. Commonly used sensors include forward biased semiconductor diodes, thermistors, thermocouples, Resistance Temperature Detectors (RTDs), radiation thermometers, fiber optic sensors, bead thermocouples and solid state sensors.
  • a thermistor is used because of its known temperature characteristics, availability and low cost.
  • the response time for the temperature sensor is less than 10 seconds per degree Celsius to minimize noise and allow the temperature measured to track the changes at the assay.
  • the analyte sensor 50 is, for example, a "primary" sensor for glucose in this application, and can also measure pH or oxygen content in this configuration through working, reference, etc., electrodes 51.
  • Attribute sensor 40(1) is a thermistor placed close to the analyte sensor 50 to measure temperature.
  • Attribute sensor 40(2) is an optical sensor-source pair to profile boundaries in the tissue to which the device 10 is attached, such as skin.
  • Attribute sensor 40(3) measures ambient light, primarily in the ultraviolet (UN) range, where damage to the assay sensor 50 is more common.
  • Attribute sensor 40(4) is a micro-durometer to measure skin conditions or properties, including tone/hardness, which is related to tissue moisture content.
  • Conditions of the tissue are useful because they indicate the degree of fluid productivity of the tissue. Dry and hard skin produces less fluid than softer skin. If the output of the micro-durometer indicates that the thickness, hardness and/or dryness of the tissue is more than normal, then the amount of suction applied to the harvesting device 10 is increased to ensure sufficient amounts of fluid is extracted. Conversely, if the output of the micro-durometer indicates that the skin is relatively soft, then the vacuum level may be maintained or decreased. This is particularly useful in a continuous monitoring system in which fluid is harvested on a continual basis from a harvesting device located on or about the same harvesting site on the tissue.
  • the sensor head 500 attaches to an assay meter 70 (FIG. 1) by an umbilical cord 510 which carries vacuum and electrical signals.
  • An attribute sensor 40(5) is provided at the meter body which measures pressure and/or vacuum and humidity in the hose inside the umbilical cord 510 that carries vacuum to the sensor head 500.
  • the attribute signal(s) of the attribute sensor(s) 40 is/are connected to a compensation element 1 10 which determines the appropriate compensation based upon the attribute signal(s) from the attribute sensor(s) 40.
  • the compensation element 110 generates an appropriate compensation that is output to a processor 80 such as a microprocessor or other computing element.
  • the analyte sensor 50 generates a measurement signal based on the type of analyte being measured.
  • the measurement signal is connected to an assay element 90 within the assay meter 70.
  • the assay element 90 performs a traditional assay of the analyte, generates a signal corresponding to this value and outputs this signal to the processor 80.
  • the processor 80 generates a corrected assay value based upon the compensation signal from the compensation element 110 and the assay signal from the assay element 90 and outputs a signal corresponding to this value to an output means 100 such as a display, a monitoring device or a signal processing device.
  • the type of compensation to the measurement made by the assay element 90 depends on the conditions sensed at the harvesting site.
  • the compensation applied may be linear or non-linear with respect to the confounding conditions, or utilize a neural network or fuzzy logic.
  • correction may be implemented using a lookup table or an equation-based algorithm. For example, pH effects the efficiency of a glucose oxidase based assay sensor for glucose measurement.
  • Humidity measurements are used in discrete sampling interval systems where the sample is assayed and then is disposed of by the system prior to the next sample being collected. Humidity measurements are also useful in this case to determine if the sample is being collected and humidity differentials are used to quantify change in concentration of the analyte being measured. Humidity measurements are also useful to quantify transepidermal water loss (TEWL). Temperature effects on the efficiency of glucose oxidase based assay are measured and used to generate a lookup table or formula to compensate the assay results for temperature variation. As described above, tissue tone and thickness measurements are useful to estimate the vacuum levels required to maintain sufficient sample flow for proper assay function. As tissue at the site becomes hydrated it will thicken and soften requiring less vacuum for equivalent sample flux.
  • FIG. 5 illustrates graphical diagrams that represent the measurement compensation process using temperature measured from a thermistor to compensate a glucose measurement.
  • the upper graph in FIG. 5 shows the conversion from the output of temperature sensor to a temperature value.
  • the lower graph in FIG. 5 shows the compensation factor for a given temperature value derived from the data in the upper graph of FIG. 5.
  • the compensation factor is applied (added or subtracted) to the glucose measurement to improve the accuracy of the glucose measurement.
  • the conversion process may be implemented in a variety of ways, including a stored lookup table of data representing the graphs shown in FIG. 5. It should be understood that each attribute may involve a compensation process that is similar to that represented by the diagrams of FIG. 5, but with different data. Similarly a multi-dimensioned lookup table may be used to efficiently map the outputs of multiple attribute sensors into a single assay compensation factor.
  • FIG. 6 shows steps in a process according to the present invention.
  • the first step 200 involves the harvesting of biological fluid for the assay.
  • Step 240 requires the acquisition of condition measurements (i.e., the attributes) relevant to the assay such as temperature, humidity, etc. This step may occur before, during or after step 200.
  • Step 280 determines the assay compensation value from the measured conditions.
  • Step 220 involves the performance of a traditional assay of analyte concentration from the fluid collected in step 200.
  • Step 260 involves the calculation of a corrected assay value by modifying the assay value determined in step 220 with a compensation or adjustment factor determined in step 280.
  • step 300 outputs the corrected assay measure for subsequent usage such as by a display or processing device.
  • a particular example of the process of FIG. 6 involves the assay of glucose.
  • Blood or interstitial fluid is harvested through microporation of the harvesting site in step 200.
  • the temperature of the analyte sensor 50 is measured.
  • Step 220 assays the harvested interstitial fluid for glucose levels using traditional assay techniques.
  • a compensation factor for the assay based upon the attribute, such as temperature, is made in step 280.
  • the compensated assay value is calculated from the traditional assay measure from step 220 and the compensation measure from step 260.
  • the compensated glucose concentration value is output in step 300.
  • a continuous analyte monitoring system such as that disclosed in PCT application No.
  • a processor 400 performs all of the calculations necessary for deriving a value from the analyte sensor 50, compensated for one or more attributes from one or more attribute sensors 40.
  • the processor 400 is a microprocessor or other programmable processing device that executes an assay program 410 to derive an assay value, compensated for the one or more attributes through the use of a compensation program or data 420.
  • the processor 400 reads a measurement signal from the analyte sensor 50 and one or more attribute signals from the attribute sensors 40, executes the assay program 410 together with the compensation program 420 to obtain a measurement value.
  • the compensation program 420 may be a mathematical algorithm or one or more lookup tables (for each attribute) as described above in conjunction with FIG. 5. This may occur on a discrete or continual basis, depending on the type of environment the system is used.
  • the value generated by the processor 400 may be coupled to a display 430. User interaction with the processor may occur through a keypad 440.
  • the system shown in FIG. 7 may further include memory to store values of attribute signals, particularly in a continual monitoring system, where it is desirable to retain an archive of information.
  • the present invention is directed to a system for detecting and measuring an analyte in a biological fluid of a animal, comprising: a harvesting device suitable for positioning on the surface of tissue of an animal to harvest biological fluid therefrom, and comprising an analyte sensor positioned to be contacted by the harvested biological fluid and which generates a measurement signal representative of the analyte; at least one attribute sensor to measure an attribute associated with the operation of the harvesting device and which generates an attribute signal representative of the attribute; and a processor coupled to the attribute sensor and the analyte sensor to receive the attribute signal and the measurement signal, wherein the processor adjusts for an operational parameter of the harvesting device based on attribute signal.
  • the present invention is directed to a method for detecting and measuring an analyte in a biological fluid of a subject, comprising steps of: harvesting biological fluid from the surface of tissue of an animal with a harvesting device; contacting an analyte sensor with the biological fluid on the tissue surface; detecting an analyte in the biological fluid with the analyte sensor; sensing an attribute associated with the operation of the harvesting device; and adjusting an operational parameter of the harvesting device based on attribute.
  • the present invention is directed to a device suitable for positioning on the surface of tissue of an animal to harvest biological fluid therefrom, and comprising: an analyte sensor positioned to be contacted by the harvested biological fluid and which generates a measurement signal representative of the analyte; and at least one attribute sensor to measure an attribute associated with the operation of the harvesting device and which generates an attribute signal representative of the attribute.

Abstract

L'invention concerne un système et un procédé de détection et de mesure d'un analyte présent dans un fluide biologique animal. Un dispositif (10) de collecte est conçu pour être positionné à la surface des tissus d'un animal en vue de la collecte de fluide biologique. Le dispositif (10) de collecte comprend un détecteur (50) d'analyte placé de manière à être au contact du fluide biologique collecté, lequel détecteur génère un signal de mesure représentatif de l'analyte. Un détecteur (40) d'attributs au moins permet de mesurer un attribut associé à l'opération de collecte de fluide biologique du dispositif (10) de collecte ou à l'analyse du fluide biologique, détecteur qui génère un signal de mesure représentatif de l'attribut. Il est possible de procéder à des ajustements des paramètres de fonctionnement du dispositif (10) de collecte sur la base d'un ou de plusieurs attributs.
PCT/US1999/020796 1998-09-10 1999-09-10 Correction d'attributs pour la detection et/ou la surveillance continue d'analytes WO2000015102A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP99945635A EP1112021A1 (fr) 1998-09-10 1999-09-10 Correction d'attributs pour la detection et/ou la surveillance continue d'analytes
CA002343762A CA2343762A1 (fr) 1998-09-10 1999-09-10 Correction d'attributs pour la detection et/ou la surveillance continue d'analytes
US09/786,830 US6918874B1 (en) 1998-09-10 1999-09-10 Attribute compensation for analyte detection and/or continuous monitoring
JP2000569690A JP4531983B2 (ja) 1998-09-10 1999-09-10 検体の検出および／または連続的監視用の属性の補償

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US9973398P 1998-09-10 1998-09-10
US60/099,733 1998-09-10
US14028399P 1999-06-18 1999-06-18
US14028599P 1999-06-18 1999-06-18
US60/140,285 1999-06-18
US60/140,283 1999-06-18

Publications (2)

Publication Number Publication Date
WO2000015102A1 true WO2000015102A1 (fr) 2000-03-23
WO2000015102A9 WO2000015102A9 (fr) 2000-10-05

Family

ID=27378892

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/020796 WO2000015102A1 (fr) 1998-09-10 1999-09-10 Correction d'attributs pour la detection et/ou la surveillance continue d'analytes

Country Status (4)

Country Link
EP (1) EP1112021A1 (fr)
JP (1) JP4531983B2 (fr)
CA (1) CA2343762A1 (fr)
WO (1) WO2000015102A1 (fr)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002024065A1 (fr) * 2000-09-22 2002-03-28 Knobbe, Lim & Buckingham Methode et appareil d'estimation et de controle en temps reel de parametres physiologiques
JP2004500948A (ja) * 2000-06-27 2004-01-15 ローズデイル　メディカル　インコーポレイテッド 被検成分モニター
JP2004522460A (ja) * 2000-06-01 2004-07-29 サイエンス　アプリケーションズ　インターナショナル　コーポレイション 健康状態をモニタリングするため、および経皮にて薬剤を送達するためのシステムおよび方法
US6790179B2 (en) 2001-08-01 2004-09-14 Johnson & Johnson Consumer Companies, Inc. Method of examining and diagnosing skin health
US6840910B2 (en) 2001-08-01 2005-01-11 Johnson & Johnson Consumer Companies, Inc. Method of distributing skin care products
US6855117B2 (en) 2001-08-01 2005-02-15 Johnson & Johnson Consumer Companies, Inc. Method of treating the skin of a subject
US6918874B1 (en) 1998-09-10 2005-07-19 Spectrx, Inc. Attribute compensation for analyte detection and/or continuous monitoring
US7141034B2 (en) 2000-06-08 2006-11-28 Altea Therapeutics Corporation Transdermal drug delivery device, method of making same and method of using same
JP2006527013A (ja) * 2003-06-06 2006-11-30 エフ ホフマン−ラ ロッシュ アクチェン ゲゼルシャフト 検査されるべき試料の一回的採取と分析のための統合テストユニット
WO2008091878A1 (fr) 2007-01-22 2008-07-31 Altea Therapeutics Corporation Système de formation de pores et de timbre transdermique et procédé d'utilisation correspondant
US7611723B2 (en) 2002-03-26 2009-11-03 Nanocyte Inc. Stinging cells expressing an exogenous polynucleotide encoding a therapeutic, diagnostic or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derived therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue
US7632522B2 (en) 2000-09-28 2009-12-15 Nanocyte Inc. Use of stinging cells/capsules for the delivery of active agents to keratinous substances
EP2168497A2 (fr) 1999-06-08 2010-03-31 Altea Therapeutics Corporation Appareil de micropores de membranes biologiques utilisant des dispositifs d'interface tissulaire à couche mince
US8062660B2 (en) 2000-09-28 2011-11-22 Nanocyte Inc. Methods compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
US8281675B2 (en) 2007-10-17 2012-10-09 Syneron Medical Ltd Dissolution rate verification
US8337493B2 (en) 2002-04-19 2012-12-25 Syneron Medical Ltd Handheld transdermal drug delivery and analyte extraction
US8834862B2 (en) 2005-04-19 2014-09-16 Nanocyte Inc. Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent
US9011419B2 (en) 2007-12-05 2015-04-21 Syneron Medical Ltd Disposable electromagnetic energy applicator
US9037229B2 (en) 2007-10-09 2015-05-19 Syneron Medical Ltd Magnetic patch coupling
US9504826B2 (en) 2009-02-18 2016-11-29 Syneron Medical Ltd Skin treatment apparatus for personal use and method for using same
US9918665B2 (en) 2002-03-11 2018-03-20 Nitto Denko Corporation Transdermal porator and patch system and method for using same
US10004434B1 (en) 2013-03-15 2018-06-26 Georgetown University Microfluidic systems for electrochemical transdermal analyte sensing using a capillary-located electrode
US11219390B2 (en) 2015-08-03 2022-01-11 Georgetown University Apparatus and method for delivery of antimicrobial during a transdermal sampling and delivery process

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030078499A1 (en) 1999-08-12 2003-04-24 Eppstein Jonathan A. Microporation of tissue for delivery of bioactive agents
US8016811B2 (en) 2003-10-24 2011-09-13 Altea Therapeutics Corporation Method for transdermal delivery of permeant substances
US7766846B2 (en) * 2008-01-28 2010-08-03 Roche Diagnostics Operations, Inc. Rapid blood expression and sampling
KR101789687B1 (ko) * 2015-06-12 2017-10-25 서울대학교산학협력단 글루코오스 조절 시스템, 상기 글루코오스 조절 시스템의 형성 방법, 및 상기 글루코오스 조절 시스템을 이용한 글루코오스 조절 방법

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000998A1 (fr) * 1989-07-07 1991-01-24 Disetronic Holding Ag Appareil de mesure du glucose
WO1994006019A1 (fr) * 1992-08-28 1994-03-17 Via Medical Corporation Solutions d'etalonnage utilisees dans les analyses de fluides biologiques et leur procede d'utilisation
WO1994014062A1 (fr) * 1992-12-11 1994-06-23 Sudor Partners Procede et appareil permettant de determiner les especes chimiques presentes dans la transpiration
WO1996000110A1 (fr) * 1994-06-24 1996-01-04 Cygnus, Inc. Dispositif et procede pour le prelevement d'echantillons par iontophorese
WO1998000193A1 (fr) 1996-07-03 1998-01-08 Altea Technologies, Inc. Microporation mecanique multiple de la peau ou de la muqueuse
US5885211A (en) 1993-11-15 1999-03-23 Spectrix, Inc. Microporation of human skin for monitoring the concentration of an analyte
WO1999044507A1 (fr) 1998-03-06 1999-09-10 Spectrx, Inc. Dispositif integre de formation de pores, de prelevement de liquide biologique et d'analyse et procede associe

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61115538A (ja) * 1984-11-10 1986-06-03 株式会社日立製作所 経皮センサ
JPH0428343A (ja) * 1990-04-27 1992-01-30 Nippondenso Co Ltd 汗中物質の測定装置

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000998A1 (fr) * 1989-07-07 1991-01-24 Disetronic Holding Ag Appareil de mesure du glucose
WO1994006019A1 (fr) * 1992-08-28 1994-03-17 Via Medical Corporation Solutions d'etalonnage utilisees dans les analyses de fluides biologiques et leur procede d'utilisation
WO1994014062A1 (fr) * 1992-12-11 1994-06-23 Sudor Partners Procede et appareil permettant de determiner les especes chimiques presentes dans la transpiration
US5885211A (en) 1993-11-15 1999-03-23 Spectrix, Inc. Microporation of human skin for monitoring the concentration of an analyte
WO1996000110A1 (fr) * 1994-06-24 1996-01-04 Cygnus, Inc. Dispositif et procede pour le prelevement d'echantillons par iontophorese
WO1998000193A1 (fr) 1996-07-03 1998-01-08 Altea Technologies, Inc. Microporation mecanique multiple de la peau ou de la muqueuse
WO1999044507A1 (fr) 1998-03-06 1999-09-10 Spectrx, Inc. Dispositif integre de formation de pores, de prelevement de liquide biologique et d'analyse et procede associe
WO1999044508A1 (fr) 1998-03-06 1999-09-10 Spectrx, Inc. Dispositif integre de formation de micropores, de prelevement et d'analyse et procede associe

Cited By (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6918874B1 (en) 1998-09-10 2005-07-19 Spectrx, Inc. Attribute compensation for analyte detection and/or continuous monitoring
EP2168497A2 (fr) 1999-06-08 2010-03-31 Altea Therapeutics Corporation Appareil de micropores de membranes biologiques utilisant des dispositifs d'interface tissulaire à couche mince
EP2286868A2 (fr) 1999-06-08 2011-02-23 Altea Therapeutics Corporation Appareil pour créer des micropores dans des membranes biologiques à l'aide d'interface de tissus minces, et procédé de fabrication
US9332937B2 (en) 2000-06-01 2016-05-10 Georgetown University Systems and methods for monitoring health and delivering drugs transdermally
JP2004522460A (ja) * 2000-06-01 2004-07-29 サイエンス　アプリケーションズ　インターナショナル　コーポレイション 健康状態をモニタリングするため、および経皮にて薬剤を送達するためのシステムおよび方法
US8568315B2 (en) 2000-06-01 2013-10-29 Georgetown University Systems and methods for monitoring health and delivering drugs transdermally
JP2013166032A (ja) * 2000-06-01 2013-08-29 Science Applications Internatl Corp 健康状態をモニタリングするため、および経皮にて薬剤を送達するためのシステムおよび方法
JP2013056209A (ja) * 2000-06-01 2013-03-28 Science Applications Internatl Corp 健康状態をモニタリングするため、および経皮にて薬剤を送達するためのシステムおよび方法
JP2011200702A (ja) * 2000-06-01 2011-10-13 Science Applications Internatl Corp 健康状態をモニタリングするため、および経皮にて薬剤を送達するためのシステムおよび方法
US7931592B2 (en) 2000-06-01 2011-04-26 Georgetown University Systems and methods for monitoring health and delivering drugs transdermally
US7141034B2 (en) 2000-06-08 2006-11-28 Altea Therapeutics Corporation Transdermal drug delivery device, method of making same and method of using same
JP2004500948A (ja) * 2000-06-27 2004-01-15 ローズデイル　メディカル　インコーポレイテッド 被検成分モニター
JP4728557B2 (ja) * 2000-06-27 2011-07-20 インチュイティ メディカル インコーポレイテッド 被検成分モニター
WO2002024065A1 (fr) * 2000-09-22 2002-03-28 Knobbe, Lim & Buckingham Methode et appareil d'estimation et de controle en temps reel de parametres physiologiques
US8062660B2 (en) 2000-09-28 2011-11-22 Nanocyte Inc. Methods compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
US8287912B2 (en) 2000-09-28 2012-10-16 Nanocyte Inc. Use of stinging cells/capsules for the delivery of active agents to keratinous substances
US8486441B2 (en) 2000-09-28 2013-07-16 Nanocyte Inc. Methods compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
US7632522B2 (en) 2000-09-28 2009-12-15 Nanocyte Inc. Use of stinging cells/capsules for the delivery of active agents to keratinous substances
US7998509B2 (en) 2000-09-28 2011-08-16 Nanocyte Inc. Use of stinging cells/capsules for the delivery of active agents to keratinous substances
US6790179B2 (en) 2001-08-01 2004-09-14 Johnson & Johnson Consumer Companies, Inc. Method of examining and diagnosing skin health
US6855117B2 (en) 2001-08-01 2005-02-15 Johnson & Johnson Consumer Companies, Inc. Method of treating the skin of a subject
US6840910B2 (en) 2001-08-01 2005-01-11 Johnson & Johnson Consumer Companies, Inc. Method of distributing skin care products
US9918665B2 (en) 2002-03-11 2018-03-20 Nitto Denko Corporation Transdermal porator and patch system and method for using same
US7392080B2 (en) 2002-03-11 2008-06-24 Altea Therapeutics Corporation Transdermal drug delivery patch system, method of making same and method of using same
EP3061492A1 (fr) 2002-03-11 2016-08-31 Nitto Denko Corporation Système de timbre d'administration transdermique de médicaments, son procédé de fabrication et d'utilisation
EP2319578A1 (fr) 2002-03-11 2011-05-11 Altea Therapeutics Corporation Système de timbre d'administration transdermique de médicaments, son procédé de fabrication et d'utilisation
US8337868B2 (en) 2002-03-26 2012-12-25 Nanocyte Inc. Stinging cells expressing an exogenous polynucleotide encoding a therapeutic, diagnostic or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derived therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue
US7611723B2 (en) 2002-03-26 2009-11-03 Nanocyte Inc. Stinging cells expressing an exogenous polynucleotide encoding a therapeutic, diagnostic or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derived therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue
US8337493B2 (en) 2002-04-19 2012-12-25 Syneron Medical Ltd Handheld transdermal drug delivery and analyte extraction
JP2006527013A (ja) * 2003-06-06 2006-11-30 エフ ホフマン−ラ ロッシュ アクチェン ゲゼルシャフト 検査されるべき試料の一回的採取と分析のための統合テストユニット
US8834862B2 (en) 2005-04-19 2014-09-16 Nanocyte Inc. Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent
EP2674188A2 (fr) 2007-01-22 2013-12-18 Altea Therapeutics Corporation Système transdermique de délivrance de perméants
EP3210646A1 (fr) 2007-01-22 2017-08-30 Nitto Denko Corporation Système d'administration transdermique de perméants
WO2008091878A1 (fr) 2007-01-22 2008-07-31 Altea Therapeutics Corporation Système de formation de pores et de timbre transdermique et procédé d'utilisation correspondant
US9037229B2 (en) 2007-10-09 2015-05-19 Syneron Medical Ltd Magnetic patch coupling
US8281675B2 (en) 2007-10-17 2012-10-09 Syneron Medical Ltd Dissolution rate verification
US9011419B2 (en) 2007-12-05 2015-04-21 Syneron Medical Ltd Disposable electromagnetic energy applicator
US9504826B2 (en) 2009-02-18 2016-11-29 Syneron Medical Ltd Skin treatment apparatus for personal use and method for using same
US10004434B1 (en) 2013-03-15 2018-06-26 Georgetown University Microfluidic systems for electrochemical transdermal analyte sensing using a capillary-located electrode
US11219390B2 (en) 2015-08-03 2022-01-11 Georgetown University Apparatus and method for delivery of antimicrobial during a transdermal sampling and delivery process

Also Published As

Publication number Publication date
EP1112021A1 (fr) 2001-07-04
JP4531983B2 (ja) 2010-08-25
WO2000015102A9 (fr) 2000-10-05
CA2343762A1 (fr) 2000-03-23
JP2003521953A (ja) 2003-07-22

Similar Documents

Publication Publication Date Title
US6918874B1 (en) Attribute compensation for analyte detection and/or continuous monitoring
EP1112021A1 (fr) Correction d'attributs pour la detection et/ou la surveillance continue d'analytes
US11571147B2 (en) Temperature-compensated analyte monitoring devices, systems, and methods thereof
US7041057B1 (en) Tissue interface device
US6549796B2 (en) Monitoring analyte concentration using minimally invasive devices
EP3733065B1 (fr) Procédé et système pour calibrer des dispositifs capteurs orthogonalement redondants
EP0702787B1 (fr) Appareil de captage biologique a procede et systeme d'evaluation de la temperature ambiante
EP2454595B1 (fr) Capteur in vivo compensé en température
US20080312859A1 (en) Method of Calibrating a System for Measuring the Concentration of Substances in Body and an Apparatus for Exercising the Method
US20080125751A1 (en) Temperature compensation for enzyme electrodes
WO2008029110A2 (fr) Dispositif
AU3510701A (en) Attribute compensation for analyte detection and/or continuou s monitoring
WO2008076574A2 (fr) Compensation de température pour des électrodes à enzyme
US20210068724A1 (en) Methods and apparatus for information gathering, error detection and analyte concentration determination during continuous analyte sensing
US11963763B2 (en) Methods and apparatus information gathering, error detection and analyte concentration determination during continuous analyte sensing
CN112716490B (zh) 一种基于加权线性回归的连续血糖校准方法及装置
US20230218204A1 (en) Personalized calibration for glucose sensing
Mastrototaro et al. Preliminary clinical results from an electroenzymatic glucose sensor implanted in subcutaneous tissue
EP1553868A1 (fr) Appareil permettant de surveiller un patient

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGES 1/5-5/5, DRAWINGS, REPLACED BY NEW PAGES 1/5-5/5; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWE Wipo information: entry into national phase

Ref document number: PA/A/2001/002601

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2343762

Country of ref document: CA

Ref document number: 2343762

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2000 569690

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1999945635

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09786830

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999945635

Country of ref document: EP

CFP Corrected version of a pamphlet front page

Free format text: REVISED ABSTRACT RECEIVED BY THE INTERNATIONAL BUREAU AFTER COMPLETION OF THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION

WWW Wipo information: withdrawn in national office

Ref document number: 1999945635

Country of ref document: EP